Does the media prefer SNWV or CTSO?

In the previous week, Sanuwave Health had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Sanuwave Health and 1 mentions for Cytosorbents. Sanuwave Health's average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanuwave Health 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INO or CTSO?

In the previous week, Inovio Pharmaceuticals and Inovio Pharmaceuticals both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 1.34 beat Cytosorbents' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, NRXS or CTSO?

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeurAxis $4.28M 19.84 -$14.63M -$0.81 N/A Cytosorbents $37.06M 0.64 -$8.20M -$0.19 N/A

Is NRXS or CTSO more profitable?

Cytosorbents has a net margin of -31.85% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Cytosorbents -31.85% -235.57% -37.88%

Does the media favor CTSO or OM?

In the previous week, Outset Medical had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Outset Medical and 1 mentions for Cytosorbents. Outset Medical's average media sentiment score of 0.93 beat Cytosorbents' score of 0.00 indicating that Outset Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Outset Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTSO or XAIR more profitable?

Cytosorbents has a net margin of -31.85% compared to Beyond Air's net margin of -432.99%. Cytosorbents' return on equity of -235.57% beat Beyond Air's return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -31.85% -235.57% -37.88% Beyond Air -432.99% -350.00% -101.34%

Cytosorbents (CTSO) Competitors

$0.38 +0.02 (+5.58%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 0.00 (-0.29%)

As of 07:56 PM Eastern

Compare

CTSO vs. SNWV, INO, NRXS, OM, and XAIR

Should you buy Cytosorbents stock or one of its competitors? MarketBeat compares Cytosorbents with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytosorbents include Sanuwave Health (SNWV), Inovio Pharmaceuticals (INO), NeurAxis (NRXS), Outset Medical (OM), and Beyond Air (XAIR). These companies are all part of the "medical equipment" industry.

How does Cytosorbents compare to Sanuwave Health?

Sanuwave Health (NASDAQ:SNWV) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Sanuwave Health has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

42.5% of Sanuwave Health shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by company insiders. Comparatively, 7.8% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Sanuwave Health had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Sanuwave Health and 1 mentions for Cytosorbents. Sanuwave Health's average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanuwave Health	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanuwave Health has a net margin of 35.96% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	35.96%	-450.56%	44.87%
Cytosorbents	-31.85%	-235.57%	-37.88%

Sanuwave Health presently has a consensus target price of $51.00, suggesting a potential upside of 696.88%. Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,314.10%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Sanuwave Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sanuwave Health has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.05M	1.25	$11.81M	$0.33	19.39
Cytosorbents	$37.06M	0.64	-$8.20M	-$0.19	N/A

Summary

Sanuwave Health beats Cytosorbents on 13 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inovio Pharmaceuticals and Inovio Pharmaceuticals both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 1.34 beat Cytosorbents' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inovio Pharmaceuticals currently has a consensus target price of $4.25, suggesting a potential upside of 289.91%. Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,314.10%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Inovio Pharmaceuticals has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
Cytosorbents	-31.85%	-235.57%	-37.88%

Inovio Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Cytosorbents has higher revenue and earnings than Inovio Pharmaceuticals. Cytosorbents is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,494.57	-$84.95M	-$1.45	N/A
Cytosorbents	$37.06M	0.64	-$8.20M	-$0.19	N/A

Summary

Cytosorbents beats Inovio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to NeurAxis?

NeurAxis (NASDAQ:NRXS) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.84	-$14.63M	-$0.81	N/A
Cytosorbents	$37.06M	0.64	-$8.20M	-$0.19	N/A

In the previous week, Cytosorbents had 1 more articles in the media than NeurAxis. MarketBeat recorded 1 mentions for Cytosorbents and 0 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score.

Company	Overall Sentiment
NeurAxis	Neutral
Cytosorbents	Neutral

Cytosorbents has a net margin of -31.85% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Cytosorbents	-31.85%	-235.57%	-37.88%

NeurAxis has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

NeurAxis presently has a consensus target price of $13.00, indicating a potential upside of 89.50%. Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,314.10%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cytosorbents beats NeurAxis on 9 of the 14 factors compared between the two stocks.

How does Cytosorbents compare to Outset Medical?

Cytosorbents (NASDAQ:CTSO) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Cytosorbents currently has a consensus price target of $5.38, indicating a potential upside of 1,314.10%. Outset Medical has a consensus price target of $10.00, indicating a potential upside of 146.31%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cytosorbents has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

Cytosorbents has higher earnings, but lower revenue than Outset Medical. Cytosorbents is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.64	-$8.20M	-$0.19	N/A
Outset Medical	$119.48M	0.63	-$81.65M	-$4.16	N/A

32.9% of Cytosorbents shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 2.5% of Outset Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Outset Medical had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Outset Medical and 1 mentions for Cytosorbents. Outset Medical's average media sentiment score of 0.93 beat Cytosorbents' score of 0.00 indicating that Outset Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Outset Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytosorbents has a net margin of -31.85% compared to Outset Medical's net margin of -63.65%. Outset Medical's return on equity of -56.13% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Outset Medical	-63.65%	-56.13%	-27.45%

Summary

Outset Medical beats Cytosorbents on 9 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Beyond Air?

Cytosorbents (NASDAQ:CTSO) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Cytosorbents has a net margin of -31.85% compared to Beyond Air's net margin of -432.99%. Cytosorbents' return on equity of -235.57% beat Beyond Air's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Beyond Air	-432.99%	-350.00%	-101.34%

Cytosorbents has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Beyond Air has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 31.5% of Beyond Air shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 10.0% of Beyond Air shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cytosorbents had 1 more articles in the media than Beyond Air. MarketBeat recorded 1 mentions for Cytosorbents and 0 mentions for Beyond Air. Cytosorbents' average media sentiment score of 0.00 equaled Beyond Air'saverage media sentiment score.

Company	Overall Sentiment
Cytosorbents	Neutral
Beyond Air	Neutral

Cytosorbents presently has a consensus target price of $5.38, indicating a potential upside of 1,314.10%. Beyond Air has a consensus target price of $200.00, indicating a potential upside of 3,244.48%. Given Beyond Air's stronger consensus rating and higher probable upside, analysts clearly believe Beyond Air is more favorable than Cytosorbents.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Beyond Air	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cytosorbents has higher revenue and earnings than Beyond Air. Cytosorbents is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.64	-$8.20M	-$0.19	N/A
Beyond Air	$7.68M	0.56	-$33.25M	-$88.00	N/A

Summary

Cytosorbents beats Beyond Air on 10 of the 15 factors compared between the two stocks.

Get Cytosorbents News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTSO vs. The Competition

Export

Metric	Cytosorbents	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.62M	$8.90B	$6.90B	$12.28B
Dividend Yield	N/A	2.49%	2.67%	9.39%
P/E Ratio	-2.00	16.04	27.10	23.94
Price / Sales	0.64	7.21	517.51	91.92
Price / Cash	N/A	18.55	26.68	47.25
Price / Book	4.22	3.26	10.66	6.14
Net Income	-$8.20M	$230.22M	$3.60B	$331.74M
7 Day Performance	0.03%	-2.87%	-1.51%	-1.72%
1 Month Performance	-13.28%	-1.97%	1.11%	-1.44%
1 Year Performance	-63.10%	0.36%	23.77%	16.97%

Cytosorbents Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTSO Cytosorbents	2.5866 of 5 stars	$0.38 +5.6%	$5.38 +1,314.1%	-65.0%	$22.62M	$37.06M	N/A	220	News Coverage
SNWV Sanuwave Health	2.5326 of 5 stars	$11.53 +2.4%	$51.00 +342.3%	-83.7%	$99.50M	$44.05M	35.06	40
INO Inovio Pharmaceuticals	2.7356 of 5 stars	$1.19 +2.2%	$4.25 +258.6%	-19.4%	$97.49M	$60K	N/A	320	News Coverage Positive News
NRXS NeurAxis	1.3958 of 5 stars	$6.97 +1.3%	$13.00 +86.5%	+157.6%	$86.43M	$4.28M	N/A	19
OM Outset Medical	3.74 of 5 stars	$4.61 +5.7%	$10.00 +116.9%	-75.9%	$85.47M	$119.48M	N/A	520	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTSO) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytosorbents (CTSO) Competitors

CTSO vs. SNWV, INO, NRXS, OM, and XAIR

How does Cytosorbents compare to Sanuwave Health?

Summary

How does Cytosorbents compare to Inovio Pharmaceuticals?

Summary

How does Cytosorbents compare to NeurAxis?

Summary

How does Cytosorbents compare to Outset Medical?

Summary

How does Cytosorbents compare to Beyond Air?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytosorbents (CTSO) Competitors

CTSO vs. SNWV, INO, NRXS, OM, and XAIR

How does Cytosorbents compare to Sanuwave Health?

Which has more volatility & risk, SNWV or CTSO?

Do insiders & institutionals hold more shares of SNWV or CTSO?

Does the media prefer SNWV or CTSO?

Is SNWV or CTSO more profitable?

Do analysts recommend SNWV or CTSO?

Which has stronger valuation and earnings, SNWV or CTSO?

Summary

How does Cytosorbents compare to Inovio Pharmaceuticals?

Do insiders and institutionals hold more shares of INO or CTSO?

Does the media prefer INO or CTSO?

Do analysts prefer INO or CTSO?

Is INO or CTSO more profitable?

Which has more volatility and risk, INO or CTSO?

Which has preferable earnings and valuation, INO or CTSO?

Summary

How does Cytosorbents compare to NeurAxis?

Which has higher earnings & valuation, NRXS or CTSO?

Does the media favor NRXS or CTSO?

Is NRXS or CTSO more profitable?

Which has more volatility and risk, NRXS or CTSO?

Do analysts recommend NRXS or CTSO?

Do insiders & institutionals have more ownership in NRXS or CTSO?

Summary

How does Cytosorbents compare to Outset Medical?

Do analysts recommend CTSO or OM?

Which has more risk & volatility, CTSO or OM?

Which has preferable earnings and valuation, CTSO or OM?

Do insiders and institutionals have more ownership in CTSO or OM?

Does the media favor CTSO or OM?

Is CTSO or OM more profitable?

Summary

How does Cytosorbents compare to Beyond Air?

Is CTSO or XAIR more profitable?

Which has more risk and volatility, CTSO or XAIR?

Do institutionals & insiders have more ownership in CTSO or XAIR?

Does the media favor CTSO or XAIR?

Do analysts recommend CTSO or XAIR?

Which has stronger valuation and earnings, CTSO or XAIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools